

Breast cancer				
Rank	Drug	Original Indication	Prob	Evidences
1	Etoposide	Testicular, Small cell lung tumors	0.986	1 , 2
2	Dacarbazine	Malignant melanoma, Hodgkin's disease	0.942	-
3	Vincristine	Acute Leukemia, Malignant Lymphoma, Hodgkin's disease	0.938	3 , 4
4	Topotecan	Ovarian cancer, Small cell lung tumors, Cervical cancer	0.906	5
5	Alitretinoin	Kaposi's sarcoma, chronic hand eczema, psoriasis	0.905	6
6	Hydrocortisone	Corticosteroid-responsive dermatoses, endocrine disorders	0.903	7
7	Cabazitaxel	Metastatic castration-resistant prostate cancer	0.886	8 , 9
8	Potassium Canrenoate	Primary hyperaldosteronism	0.878	10 , 11
9	Prednisone	Immune-mediated reactions, endocrine/neoplastic diseases	0.841	12
10	Bicalutamide	Stage D2 metastatic carcinoma of the prostate	0.782	13 , 14

References

1. Sledge GW Jr. Etoposide in the management of metastatic breast cancer. *Cancer*. 1991;67(1 Suppl):266-270. doi:10.1002/1097-0142(19910101)67:1+<266::aid-cnrc2820671310>3.0.co;2-a
2. Atienza DM, Vogel CL, Trock B, Swain SM. Phase II study of oral etoposide for patients with advanced breast cancer. *Cancer*. 1995;76(12):2485-2490. doi:10.1002/1097-0142(19951215)76:12<2485::aid-cnrc2820761212>3.0.co;2-j
3. Zeng F, Ju RJ, Liu L, Xie HJ, Mu LM, Lu WL. Efficacy in Treating Lung Metastasis of Invasive Breast Cancer with Functional Vincristine Plus Dasatinib Liposomes. *Pharmacology*. 2018;101(1-2):43-53. doi:10.1159/000480737
4. Zeng F, Ju RJ, Liu L, et al. Application of functional vincristine plus dasatinib liposomes to deletion of vasculogenic mimicry channels in triple-negative breast cancer. *Oncotarget*. 2015;6(34):36625-36642. doi:10.18632/oncotarget.5382
5. Chang AY. The potential role of topotecan in the treatment of advanced breast cancer. *Semin Oncol*. 1997;24(6 Suppl 20):S20-S54.
6. Lawrence JA, Adamson PC, Caruso R, et al. Phase I clinical trial of alitretinoin and tamoxifen in breast cancer patients: toxicity, pharmacokinetic, and biomarker evaluations. *J Clin Oncol*. 2001;19(10):2754-2763. doi:10.1200/JCO.2001.19.10.2754
7. Antonova L, Mueller CR. Hydrocortisone down-regulates the tumor suppressor gene BRCA1 in mammary cells: a possible molecular link between stress and breast cancer. *Genes Chromosomes Cancer*. 2008;47(4):341-352. doi:10.1002/gcc.20538
8. Koutras A, Zagouri F, Koliou GA, et al. Phase 2 study of cabazitaxel as second-line treatment in patients with HER2-negative metastatic breast cancer previously treated with taxanes-a Hellenic Cooperative Oncology Group (HeCOG) Trial. *Br J Cancer*. 2020;123(3):355-361. doi:10.1038/s41416-020-0909-4
9. Zhong T, He B, Cao HQ, et al. Treating breast cancer metastasis with cabazitaxel-loaded polymeric micelles. *Acta Pharmacol Sin*. 2017;38(6):924-930. doi:10.1038/aps.2017.36
10. Obradović, M.M.S., Hamelin, B., Manevski, N. et al. Glucocorticoids promote breast cancer metastasis. *Nature* **567**, 540–544 (2019). <https://doi.org/10.1038/s41586-019-1019-4>
11. Mitre-Aguilar IB, Moreno-Mitre D, Melendez-Zajgla J, et al. The Role of Glucocorticoids in Breast Cancer Therapy. *Curr Oncol*. 2022;30(1):298-314. Published 2022 Dec 25. doi:10.3390/curroncol30010024
12. Cairat, M., Al Rahmoun, M., Gunter, M.J. et al. Use of systemic glucocorticoids and risk of breast cancer in a prospective cohort of postmenopausal women. *BMC Med* **19**, 186 (2021). <https://doi.org/10.1186/s12916-021-02004-6>
13. Gucalp A, Tolaney S, Isakoff SJ, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic Breast Cancer. *Clin Cancer Res*. 2013;19(19):5505-5512.

doi:10.1158/1078-0432.CCR-12-3327

14. Lu Q, Xia W, Lee K, et al. Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor-Positive/Androgen Receptor-Positive Advanced Breast Cancer. *Oncologist*. 2020;25(1):21-e15. doi:10.1634/theoncologist.2019-0564